top of page

Marengo Therapeutics has presented data at ESMO and SITC showing that its lead program, which is designed to activate Vβ6/10 T cells, is active in multiple tumor types

  • Nov 7, 2025
  • 1 min read

CEO Zhen Su walks us through the data, which had 46 efficacy-evaluable patients and showed a 20% ORR and 80% DCR across multiple tumor types.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page